RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target

Benzinga Newsdesk www.benzinga.com Positive 51.1%

Neg 0% Neu 0% Pos 51.1%

RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.